Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

214
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
214
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

200
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
200
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

215
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
215
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

155
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
155
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

177
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
177
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

684
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
684

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Memoriam:DonaldW.Lewis,MD(1951–2012).

Seminars in pediatric neurology·2016
Same author

Medical Comorbidities in Pediatric Headache.

Seminars in pediatric neurology·2016
Same author

Pediatric headache: where have we been and where do we need to be.

Headache·2014
Same author

In memoriam: Donald W. Lewis, MD (1951-2012).

Headache·2012
Same author

Pediatric headache: a clinical review.

Headache·2012
Same author

Common presentations of chronic daily headache in adolescents.

Pediatric annals·2010
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Videos

Pediatric headache.

Jack Gladstein1

  • 1Department of Pediatrics and Neurology, Pediatric Headache Clinic, University of Maryland School of Medicine, 22 South Greene Street, Room N5W69, Baltimore, MD 21201, USA. jgladstein@peds.umaryland.edu.

Current Treatment Options in Neurology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Pediatric migraine is treatable with early intervention, trigger avoidance, and medication. Triptans are safe for children and adolescents, and prophylactic drugs are recommended for significant disability.

Related Experiment Videos

Area of Science:

  • Pediatric Neurology
  • Headache Medicine

Background:

  • Migraine significantly impacts children and adolescents.
  • Effective management strategies are crucial for this population.

Purpose of the Study:

  • To outline the principles for treating migraine in pediatric populations.
  • To discuss the role of pharmacologic and non-pharmacologic interventions.

Main Methods:

  • Review of current treatment guidelines and clinical evidence.
  • Focus on early intervention, trigger identification, and medication use.
  • Consideration of comorbidities in drug selection.

Main Results:

  • Migraine is highly treatable in children and adolescents.
  • Triptans demonstrate safety and efficacy in this age group, despite lacking formal US pediatric indications.
  • Prophylactic medications are indicated for significant migraine-related disability.

Conclusions:

  • A multi-faceted approach including non-pharmacologic therapies is essential.
  • Judicious use of medications, including triptans and prophylactic agents, is key.
  • Treatment should be individualized based on patient comorbidities and disability levels.